MaaT Pharma Aktie
| 0,95EUR | 0,02EUR | 1,82% |
WKN DE: A3C7A5 / ISIN: FR0012634822
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 59 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,08 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 47 | 42 | 32 | 28 | 33 |
| Summe Anlagevermögen | 2 | 3 | 11 | 11 | 12 |
| Summe Aktiva | 49 | 45 | 43 | 39 | 45 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 10 | 18 | 22 | 28 | 43 |
| Summe Eigenkapital | 40 | 27 | 20 | 10 | 2 |
| Summe Passiva | 49 | 45 | 43 | 39 | 45 |
Adresse
| 70, Avenue Tony Garnier, 69007 Lyon | |
| Telefon | +33 (4) 28-29-14-00 |
| Internet | http://www.maatpharma.com |
Management
|
Carole Schwintner
Chief Technology Officer |
|
Claude Bertrand
Independent Director |
|
Emilie Plantamura
Deputy Chief Medical Officer |
|
Eric Soyer
Chief Financial Officer |
|
Fr?d?ric Fasano
Chief Strategy & Corporate Development Officer |
|
Hervé Affagard
Chief Executive Officer & Director |
|
Isabelle de Cremoux
Non-Independent Non-Executive Director |
|
Jean Volatier
Independent Director |
|
Jean-Marie Lefèvre
Chairman |
|
Muriel Prudent
Non-Executive Director |
|
Nadia Kamal
Independent Director |
|
Sheri Simmons
Chief Scientific Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.